Atg4b-Dependent Autophagic Flux Alleviates Huntington’s Disease Progression

• Catia C. Proenca,

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯
• Natacha Stoehr,

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯
• Mario Bernhard,

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯
• Shanon Seger,

  Current address: Actelion Pharmaceuticals Allschwil, Switzerland

  Affiliation Novartis Pharma AG Basel, Switzerland

  ⨯
• Christel Genoud,

  Affiliation Friedrich Miescher Institute Basel, Switzerland

  ⨯
• Ana Roscic,

  Affiliation Novartis Pharma AG Basel, Switzerland

  ⨯
• Paolo Paganetti,

  Current address: AC Immune SA Lausanne, Switzerland

  Affiliation Novartis Pharma AG Basel, Switzerland

  ⨯
• Shanming Liu,

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯
• Leon O. Murphy,

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯
• Rainer Kuhn,

  Current address: IRBM Promidis Pomezia, Italy

  Affiliation Novartis Pharma AG Basel, Switzerland

  ⨯
• Tewis Bouwmeester,

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯
• Ivan Galimberti

  * E-mail: ivan.galimberti@novartis.com

  Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland

  ⨯